Get the Stockscreener App
9.25
0.43%
-0.10
Alpha Cognition Inc stock is traded at $9.25, with a volume of 11,741.
It is down -0.43% in the last 24 hours and down -17.17% over the past month.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
See More
Previous Close:
$9.35
Open:
$9.45
24h Volume:
11,741
Relative Volume:
0.12
Market Cap:
$145.62M
Revenue:
-
Net Income/Loss:
$-14.72M
P/E Ratio:
-3.2686
EPS:
-2.83
Net Cash Flow:
$-7.41M
1W Performance:
+2.20%
1M Performance:
-17.17%
6M Performance:
+61.35%
1Y Performance:
+0.00%
1-Day Range:
$9.245
$9.45
1-Week Range:
$8.48
$10.15
52-Week Range:
$3.75
$11.54
Alpha Cognition Inc Stock (ACOG) Company Profile
Name
Alpha Cognition Inc
Sector
Industry
Phone
(858) 344-4375
Address
1200-750 W PENDER ST, VANCOUVER
Compare ACOG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
9.25 | 145.62M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.34 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.49 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.20 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.01 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | H.C. Wainwright | Buy |
Alpha Cognition Inc Stock (ACOG) Latest News
Using portfolio simulators with Alpha Cognition Inc. includedLong-Term Growth Trend Summary With Confidence - Newser
Is Alpha Cognition Inc. stock entering bullish territoryFree High Return Stock Focus With Safety - Newser
How to build a dashboard for Alpha Cognition Inc. stockFree Buy Signal Based on Chart Analysis - Newser
Will Alpha Cognition Inc. continue its uptrendTrend Reversal Watch with Entry Signals - Newser
Detecting price anomalies in Alpha Cognition Inc. with AISwing Trade Entry and Exit Point Analysis - Newser
What candlestick patterns are forming on Alpha Cognition Inc.Bull Market Summary and Recovery Outlook - Newser
Alpha Cognition Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingAI Triggered Buy Zone Forecast System - Newser
How Alpha Cognition Inc. stock performs during market volatilityPattern Recognition Based Market Move Prediction - Newser
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview - Business Wire
Comparing Alpha Cognition Inc. in custom built stock radarsPrice Action Trading with Volume Confirmation - Newser
What is the dividend policy of Alpha Cognition Inc. stockInvest smarter with advanced market data - Jammu Links News
Should you wait for a breakout in Alpha Cognition Inc.Momentum Prediction Based on AI Backtesting - Newser
Chart based exit strategy for Alpha Cognition Inc.Real Time Alert System for Market Moves - Newser
How many analysts rate Alpha Cognition Inc. as a “Buy”Capitalize on momentum-driven opportunities - Jammu Links News
What are analysts’ price targets for Alpha Cognition Inc. in the next 12 monthsAchieve breakthrough investment performance - Jammu Links News
Does Alpha Cognition Inc. stock perform well during market downturnsAccelerated earnings growth - Jammu Links News
What are the latest earnings results for Alpha Cognition Inc.Skyrocketing investment returns - Jammu Links News
What drives Alpha Cognition Inc. stock priceIdentify undervalued stocks ready to soar - Jammu Links News
When is Alpha Cognition Inc. stock expected to show significant growthHigh-yield growth strategies - Jammu Links News
How volatile is Alpha Cognition Inc. stock compared to the marketTremendous growth potential - Jammu Links News
What is Alpha Cognition Inc. company’s growth strategyBreakout Stocks Signals Backed By Experts - jammulinksnews.com
What technical models suggest about Alpha Cognition Inc.’s comebackBuy Signal Forecast With Short-Term Data - Newser
Why Alpha Cognition Inc. stock attracts strong analyst attentionTrend Confirmation Scanner with Entry Focus - Newser
Individual investors account for 40% of Alpha Cognition Inc.'s (NASDAQ:ACOG) ownership, while hedge funds account for 27% - Yahoo Finance
Alpha Cognition: Unheralded Canadian Pharma Set To Launch Alzheimer's Drug - Seeking Alpha
Is Alpha Cognition Inc. stock a good hedge against inflationFree ROI Driven Equity Selection With Safety - Newser
Alpha Cognition Inc. Reversal Rally May Surprise BearsTechnical Entry Strategy for Beginners Explained - metal.it
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease - BioSpace
Alpha Cognition’s Alzheimer’s drug application accepted for review in China - Investing.com Australia
Alpha Cognition’s Alzheimer’s drug application accepted for review in China By Investing.com - Investing.com Nigeria
Alpha Cognition announces CMS Zunveyl NDA accepted for review by NMPA - TipRanks
Alpha Cognition Inc’s Strategic Developments and Market Potential Drive Buy Rating - TipRanks
How strong is Alpha Cognition Inc. company’s balance sheetAI Powered Tips For 2025 - jammulinksnews.com
Alpha Cognition Inc Stock (ACOG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alpha Cognition Inc Stock (ACOG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
0.46%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):